rapcabtagene autoleucel (YTB323)
Sponsors
Novartis Pharmaceuticals, Stanford University
Conditions
Large-cell LymphomaProgressive Multiple SclerosisRelapsing Multiple Sclerosis
Phase 1
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Active, not recruitingNCT06617793
Start: 2025-02-24End: 2030-08-07Target: 28Updated: 2026-09-02
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Active, not recruitingNCT06675864
Start: 2024-12-12End: 2030-06-14Target: 28Updated: 2026-09-04
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Not yet recruitingNCT07443137
Start: 2026-09-01End: 2028-08-01Target: 20Updated: 2026-08-27